Why Harmony Biosciences Stock Got Mashed on Monday

Impact · against what's priced in

The leadership transition at Harmony Biosciences introduces a new execution risk premium not previously modeled, while the reiteration of Wakix revenue guidance confirms existing valuation baselines. The stock's decline reflects a market preference for the outgoing CEO's track record over the planned succession.

HRMY−0.20

Not in the price yet

The price assumes

Current Wakix (pitolisant) revenue and cash generation

The planned CEO transition to Peter Anastasiou in 2027 introduces a leadership risk premium that the market is currently pricing in via a 5% drop. The reiteration of $1B-$1.04B revenue guidance for Wakix confirms the existing business base the price already assumes.

What HRMY's price assumes · Sep 14

• biotech
• healthcare
• pharmaceuticals
• HRMY
• ceo succession
• management change
• revenue guidance

Search tags